Document Detail


Bevacizumab Use for Recurrent High-Grade Glioma at McGill University Hospital.
MedLine Citation:
PMID:  23419575     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Background: Bevacizumab, a humanized recombinant anti-vascular endothelial growth factor antibody, was approved in Canada in 2010 for the treatment of high-grade glioma. We report the effectiveness and safety of bevacizumab in the treatment of patients with recurrent high-grade gliomas at a single institution. Methods: Twenty-seven consecutive patients with high-grade glioma (anaplastic glioma and glioblastoma) at first or subsequent relapse were treated with bevacizumab alone or in combination with chemotherapy. The primary endpoint was progression-free survival (PFS) and secondary endpoints were objective response rate, six month PFS, overall survival (OS), and safety profile. Results: The clinical benefit rate (complete and partial responses plus stable disease) was 59%. Median PFS was 4.3 (95% CI, 3.0-10.9) months, with a six month PFS rate of 43%. Median OS after current relapse was 8.9 (95% CI, 5.8-not reached) months. Ten episodes of grade 3/4 adverse events were observed in nine patients, including fatigue (n = 3), thrombocytopenia (n = 4), and myelotoxicity, febrile neutropenia, and pulmonary embolism (each n = 1). Conclusions: We consider the efficacy and safety profile of bevacizumab is comparable to other cohorts of patients treated for recurrent high-grade glioma at other international institutions.
Authors:
Solmaz Sahebjam; Evgenia Garoufalis; Marie-Christine Guiot; Thierry Muanza; Rolando Del Maestro; Kevin Petrecca; Rajesh Sharma; Petr Kavan
Related Documents :
23940635 - Chemoirradiation for glioblastoma multiforme: the national cancer institute experience.
23042095 - Prognostic significance of timp3 hypermethylation in post-treatment salivary rinse from...
23456385 - Extensive cytoreductive surgery for appendiceal carcinomatosis: morbidity, mortality, a...
23057495 - Phase ii study of preoperative chemoradiation with s-1 plus oxaliplatin in patients wit...
15017545 - Right congenital diaphragmatic hernia: prenatal assessment and outcome.
9209665 - Phase i/ii study of the combination of carboplatin and paclitaxel as first-line chemoth...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques     Volume:  40     ISSN:  0317-1671     ISO Abbreviation:  Can J Neurol Sci     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-02-19     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0415227     Medline TA:  Can J Neurol Sci     Country:  Canada    
Other Details:
Languages:  eng     Pagination:  241-6     Citation Subset:  IM    
Affiliation:
Drug Development Program, Princess Margaret Hospital, Toronto, Ontario.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The syndrome of infantile-onset saccade initiation delay.
Next Document:  Shab K (+) channel slow inactivation: a test for U-type inactivation and a hypothesis regarding K (+...